Steven D. Rubin

September 28, 2026

Entera Bio gets new coverage from Guggenheim and Cantor. Guggenheim has started coverage of Entera Bio, giving it a buy rating and a target price of $11. Cantor Fitzgerald also began coverage, assigning an overweight rating. These new ratings come as the stock trades near its 52‑week low and shows a moderate RSI of 40, indicating room for movement.

October 16, 2026

OPKO Health Shares Rise on $722M BioReference Asset Sale. OPKO Health announced it sold BioReference laboratory assets to Labcorp for $722 million, a key part of Labcorp’s up to $872 million acquisition. The transaction was reflected in a sharp increase in OPKO’s stock price. The deal highlights OPKO’s focus on divesting non‑core assets. The move follows Labcorp’s broader strategy to expand its laboratory services.

October 15, 2026

Red Violet Gains Attention as RegTech Stock After BofA Penalty. Red Violet is highlighted among RegTech stocks following Bank of America’s $1.2 b penalty. Analysts note improving fundamentals and strong growth prospects, with a 52‑week range of $33.40–$81.80 and a trailing P/E of 78.0. The company’s target price averages $84.50, suggesting upside potential for growth‑focused investors.

September 29, 2026

Eloxx Pharmaceuticals Included in Pre-Market Movers List. Eloxx Pharmaceuticals was featured in a recent roundup of healthcare stocks showing movement during Monday's pre-market session. The company currently trades with a low trailing P/E ratio of 5.3, which is significantly below the average analyst target price of $38.25. This inclusion highlights current market attention on the stock, though the specific drivers for the pre-market activity are not detailed in the provided report.

September 27, 2026

NAGE linked to new preclinical study on CD38 and NAD+ decline. A new preclinical study identified CD38 as a driver of age‑related NAD+ decline and showed that nicotinamide riboside can improve pregnancy outcomes in animal models. The research also reported lower NAD+ levels in placental tissue from older mothers. Niagen Bioscience clarified that it did not conduct, fund, or design the study and that the NR used was not its proprietary Niagen ingredient. The findings relate to the company’s focus on NAD+‑boosting products and may draw attention to its pipeline.